BP 1209
Alternative Names: BP-1209Latest Information Update: 29 May 2022
At a glance
- Originator BrightPath Biotherapeutics
- Class Antibodies; Antineoplastics; Cancer vaccines; Conjugate vaccines; Immunoconjugates; Immunoglobulin Fc fragments; Immunotherapies; Peptides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 08 Apr 2022 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 113th annual meeting of the American Association for Cancer Research (AACR-2022)
- 05 Oct 2021 BP 1209 is available for licensing as of 05 Oct 2021. https://www.brightpathbio.com
- 01 Oct 2021 Pre-clinical research in Solid tumours in Japan (parenteral) as of October 2021 (BrightPath Biotherapeutics pipeline; October 2021)